Dianthus Therapeutics (DNTH) EBIT Margin (2022 - 2025)
Historic EBIT Margin for Dianthus Therapeutics (DNTH) over the last 4 years, with Q3 2025 value amounting to 10173.74%.
- Dianthus Therapeutics' EBIT Margin fell 87971300.0% to 10173.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 4558.41%, marking a year-over-year decrease of 30044500.0%. This contributed to the annual value of 1633.74% for FY2024, which is 709300.0% up from last year.
- Dianthus Therapeutics' EBIT Margin amounted to 10173.74% in Q3 2025, which was down 87971300.0% from 18096.89% recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' EBIT Margin ranged from a high of 703.67% in Q3 2022 and a low of 18096.89% during Q2 2025
- In the last 4 years, Dianthus Therapeutics' EBIT Margin had a median value of 1705.52% in 2023 and averaged 3631.93%.
- In the last 5 years, Dianthus Therapeutics' EBIT Margin skyrocketed by 6343800bps in 2024 and then plummeted by -169050500bps in 2025.
- Dianthus Therapeutics' EBIT Margin (Quarter) stood at 910.04% in 2022, then plummeted by -234bps to 3041.31% in 2023, then increased by 21bps to 2406.94% in 2024, then tumbled by -323bps to 10173.74% in 2025.
- Its EBIT Margin was 10173.74% in Q3 2025, compared to 18096.89% in Q2 2025 and 2852.71% in Q1 2025.